Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Q4 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Alpine Immune Sciences Fourth Quarter 2023 and Full-Year Earnings Call. Currently, all participants are in a listen-only mode.
Alpine Immune Sciences Inc. (ALPN)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Decheng Capital Min Cui | 8,317,924 | $329,722,507 | +18% | 44.21% |
| 2. | VenBio Select Advisor Kurt Von Emster | 5,775,000 | $228,921,000 | 2.67% | |
| 3. | Cormorant Asset Management Bihua Chen | 2,700,000 | $107,028,000 | +6% | 4.69% |
| 4. | OrbiMed Advisors Samuel Isaly | 2,680,496 | $106,254,861 | +6% | 1.94% |
| 5. | Lynx1 Capital Management Weston Nichols | 2,253,183 | $89,316,174 | -41% | 23% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.10 | 112,665 | Large Shareholder | 1,484,115 | 2022-02-11 | Filing | |
| $10.17 | 1,900 | Director | 1,900 | 2021-09-23 | Filing | |
| $10.08 | 15,000 | Director | 50,000 | 2021-09-23 | Filing | |
| $9.80 | 10,000 | Director | 35,000 | 2021-09-21 | Filing | |
| $9.40 | 425,531 | Large Shareholder, Director | 425,531 | 2021-09-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $64.57 | 19 | 2,829,347 | 2024-04-25 | Filing | ||
| $25.00 | 44,000 | Officer | 0 | 2024-01-26 | Filing | |
| $22.31 | 73,764 | Officer | 0 | 2024-01-26 | Filing | |
| $22.00 | 236 | Officer | 0 | 2024-01-25 | Filing | |
| $20.04 | 1,016 | Officer, Director | 0 | 2023-12-28 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,176,743 | $60,548,722 | 2.83% | |
| 2. | 3,131,008 | $59,677,012 | 3.19% | |
| 3. | 3,058,498 | $58,294,972 | 0% | |
| 4. | 2,234,767 | $42,594,660 | 0% | |
| 5. | 1,390,029 | $26,493,953 | 0% |
News See All
5 Best Booming Stocks to Buy Right Now
Seattle, Washington-based Alpine Immune Sciences Inc (NASDAQ:ALPN) ranks fifth in our list of the best booming stocks to buy right now.
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Q4 2022 Earnings Call Transcript
Operator: Welcome to the Alpine Immune Sciences Fourth Quarter 2022 Earnings Call. Currently, all participants are in listen-only mode. As a reminder, this event is being recorded.
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Q3 2022 Earnings Call Transcript
Operator: Welcome to the Alpine Immune Sciences Third Quarter Earnings Call. Currently all participants are in a listen-only mode. As a reminder, this event is being recorded.
Hedge Fund and Insider Trading News: GoldenTree Asset Management, Third Point LLC, HITE, Mountain Province Diamonds, Inc. (MPVDF), ComSovereign Holding Corp (COMS), and More
Pierre de Chillaz, a former partner at GoldenTree Asset Management, is preparing to start his own hedge fund, joining a growing list of startups as investors return to the industry.
Were Hedge Funds Right About Alpine Immune Sciences, Inc. (ALPN)?
In this article we are going to use hedge fund sentiment as a tool and determine whether Alpine Immune Sciences, Inc. (NASDAQ:ALPN) is a good investment right now.
Is ALPN A Good Stock To Buy Now?
We at Insider Monkey have gone over 817 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of September...
Hedge Funds Never Been Less Bullish On Alpine Immune Sciences, Inc. (ALPN)
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
Is Alpine Immune Sciences, Inc. (ALPN) A Good Stock To Buy?
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts, usually don't make them change their opinion towards ...
13D Filing: OrbiMed Advisors and Alpine Immune Sciences Inc. (ALPN)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of § 240.13d‑1(e), 240....
Billionaire Hedge Funds
